FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2560-2562 December 25, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The dramatic increase in the incidence of type 2 diabetes mellitus and obesity in the Western world signals the beginning of an epidemic that is expected to become a major cause of illness and death. At the heart of this problem lies insulin resistance, the earliest detectable abnormality in the development of diabetes. Many states give rise to insulin resistance, and all are explained by numerous mechanisms in which insulin signaling is decreased. Du et al.¹ have recently described another, involving a protein they call TRB3 that specifically blocks the actions of insulin in the liver.

Insulin is the master . . . [Full Text of this Article]

Source Information

From the Life Sciences Institute, University of Michigan, Ann Arbor.

This article has been cited by other articles:

• Ferreira, I. A., Mocking, A. I.M., Feijge, M. A.H., Gorter, G., van Haeften, T. W., Heemskerk, J. W.M., Akkerman, J.-W. N. (2006). Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus. Arterioscler. Thromb. Vasc. Bio. 26: 417-422 [Abstract] [Full Text]